← Leaderboards
Leanne Groban
Wake Forest University Health Sciences
$7,151,172
Attributed
$7,369,158
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $940.2K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$7,369,158 · 7
By mechanism
P01$3,104,519 · 2
R01$2,754,257 · 1
K08$858,480 · 1
R21$435,972 · 1
R03$215,930 · 2
Top collaborators
- Emmanuel C. Opara2 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Emmanuel C. Opara$2,148,324
Others in their field
Top investigators on “Hypertension”
- Chanza Baytop · Westat, Inc.$271,217,917
- Paula Darby Lipman · Westat, Inc.$52,914,492
- Walter N Kernan · Yale University$42,197,025
- Rohit Varma · University Of Southern California$35,266,606
- Susan S Redline · Brigham And Women'S Hospital$35,248,244
- Marlene Rabinovitch · Stanford University$34,807,202
Research focus
HypertensionCardiacRattusVentricularHeart FailureStructureMolecularHeartFunctional DisorderLeftResearch PersonnelPressureLeft Ventricular RemodelingEstrogen ReceptorsAgingMenopauseWomanPostmenopauseFemaleEstrogensPathway InteractionsTissuesFibrosisRenin-Angiotensin System
Grant awards (29)
Effects of cell-based hormone therapy on LV diastolic dysfunction and hypertrophy progression after mid-life estrogen loss$203,472
R21 · FY2020 · AG · contact PI
Molecular and Biochemistry Core Facility$321,150
P01 · FY2019 · HL · contact PI
Estrogen/GPR30 Modulation of Cardiac RAS Metabolism in Sex-Specific Hypertensive$282,231
P01 · FY2019 · HL · contact PI
Effects of cell-based hormone therapy on LV diastolic dysfunction and hypertrophy progression after mid-life estrogen loss$232,500
R21 · FY2019 · AG · contact PI
Molecular and Biochemistry Core Facility$343,042
P01 · FY2018 · HL · contact PI
Estrogen/GPR30 Modulation of Cardiac RAS Metabolism in Sex-Specific Hypertensive$302,529
P01 · FY2018 · HL · contact PI
Molecular and Biochemistry Core Facility$332,340
P01 · FY2017 · HL · contact PI
Interplay Between Estrogen, GPR30 and Chymase/RAS in Diastolic Function$317,750
R01 · FY2017 · AG · contact PI
Estrogen/GPR30 Modulation of Cardiac RAS Metabolism in Sex-Specific Hypertensive$290,111
P01 · FY2017 · HL · contact PI
Molecular and Biochemistry Core Facility$321,734
P01 · FY2016 · HL · contact PI
Interplay Between Estrogen, GPR30 and Chymase/RAS in Diastolic Function$317,750
R01 · FY2016 · AG · contact PI
Estrogen/GPR30 Modulation of Cardiac RAS Metabolism in Sex-Specific Hypertensive$294,446
P01 · FY2016 · HL · contact PI
Molecular and Biochemistry Core Facility$321,734
P01 · FY2015 · HL · contact PI
Interplay Between Estrogen, GPR30 and Chymase/RAS in Diastolic Function$308,217
R01 · FY2015 · AG · contact PI
Estrogen/GPR30 Modulation of Cardiac RAS Metabolism in Sex-Specific Hypertensive$295,202
P01 · FY2015 · HL · contact PI
Interplay Between Estrogen, GPR30 and Chymase/RAS in Diastolic Function$315,700
R01 · FY2014 · AG · contact PI
Interplay Between Estrogen, GPR30 and Chymase/RAS in Diastolic Function$313,650
R01 · FY2013 · AG · contact PI
The conditional GPR30 knockout mouse: a model of female-specific cardiac aging$69,930
R03 · FY2013 · AG · contact PI
Estrogen, Angiotensin-(1-7), and Diastolic Function$288,712
R01 · FY2012 · AG · contact PI
The conditional GPR30 knockout mouse: a model of female-specific cardiac aging$74,000
R03 · FY2012 · AG · contact PI
Estrogen, Angiotensin-(1-7), and Diastolic Function$288,712
R01 · FY2011 · AG · contact PI
Estrogen, Angiotensin-(1-7), and Diastolic Function$300,366
R01 · FY2010 · AG · contact PI
Estrogen, Angiotensin-(1-7), and Diastolic Function$303,400
R01 · FY2009 · AG · contact PI
Growth Hormone, Angiotensin II, and Cardiac Aging$174,960
K08 · FY2009 · AG · contact PI
Growth Hormone, Angiotensin II, and Cardiac Aging$174,960
K08 · FY2008 · AG · contact PI
Growth Hormone, Angiotensin II, and Cardiac Aging$172,800
K08 · FY2007 · AG · contact PI
Growth Hormone, Angiotensin II, and Cardiac Aging$169,560
K08 · FY2006 · AG · contact PI
Growth Hormone, Angiotensin II, and Cardiac Aging$166,200
K08 · FY2005 · AG
Role of IGF-1 In Diastolic Dysfunction of Aging$72,000
R03 · FY2003 · AG